Navigation Links
Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting
Date:12/6/2011

e "EMA"), the potential failure of tosedostat to prove safe and effective for the treatment of AML, myelodysplastic syndromes, multiple myeloma, blood related cancers and solid tumors as determined by the FDA and/or the EMA, that the FDA may not accept the proposed clinical trial of tosedostat and/or may request additional trials, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials,  determinations by regulatory, patent, and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing, and selling pixantrone and tosedostat, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

 

 

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:

T: 800.715.0944
E: info@askarm.com

 


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
2. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
3. New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions
4. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
5. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
6. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
7. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
10. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
11. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... , ROCKVILLE, Md., Dec. 9 Novavax, ... 25, 2009, it closed its previously announced public offering of ... Novavax received net proceeds from the sale of the ... approximately $21 million, which will be used for preclinical studies ...
... , GAITHERSBURG, Md, Dec. 9 Lentigen Corporation, ... of lentiviral gene delivery technologies, announced today that it ... business innovation research (SBIR) grant for a program on ... using Lentivirus". In this program, Lentigen will collaborate ...
Cached Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:9/1/2014)... Steven Reinberg ... News) -- In a head-to-head comparison, an experimental drug ... and hospitalizations in heart failure patients. According to ... of the marked benefit of the new drug, dubbed ... those getting the standard medication, enalapril (Vasotec), either died ...
(Date:9/1/2014)... An operating theatre or operating room is ... operations. An operating room comprises a myriad of specially-designed ... lights, imaging displays as well as integration systems for ... Research, a U.S.-based market research firm, the operating room ... by 2019. , According to this report, the ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Bioinformatics ... organize and analyze biological and genetic data. A ... activity of developing software tools to generate and ... be confused with biological computation. While bioinformatics simply ... of biology can its related concepts, biological computation ...
(Date:9/1/2014)... 2014 Ontraport , one of ... was developed to automate the small intricacies of managing ... Shane Michaels, prompting an investigative review. , “As ... of managing all of the small details involved with ... reports Michaels. “That’s why Ontraport has become so popular ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... , , , ... part of Mayo Clinic and Microsoft Corp.,s shared vision to help ... made enhancements to Mayo Clinic Health Manager , ... manage their health. People with conditions such as hypertension and high ...
... Germany: For the first time researchers have shown that by ... possible to make pancreatic cancer cells sensitive to chemotherapy, opening ... treat the disease. Dr Davide Melisi told Europe,s ... Berlin today (Thursday 24 September) that resistance to chemotherapy was ...
... New Series ... iPod touch. , ... (Vocus) September 24, 2009 -- Modality, Inc. and Elsevier, Inc. today announced two Procedures Consult ... help physicians, medical residents and students prepare for, perform and test their knowledge of the ...
... ... leader in automatic door sensors, BEA, Inc. is delighted our products will be welcoming ... center in the world with Gold LEED® (Leadership in Energy and Environmental Design) certification. ... Pittsburgh, Pa. ...
... ... is featured in a presentation and free downloadable slides on the Diabetes Best Practices ... Somerville, ... illnesses should focus on self-care and give them the survival skills necessary to maintain ...
... AMSTERDAM, September 24 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... Jorn Aldag as its new Chief Executive Officer, starting,October ... in the life,sciences sector and more than twenty five ... President and CEO of Evotec AG, he was,instrumental in ...
Cached Medicine News:Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3Health News:Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 3Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:New Presentation Highlights Importance of In-Hospital Hyperglycemia Management and Appropriate Discharge Planning for Diabetes Patients 2Health News:AMT Appoints New Chief Executive Officer 2Health News:AMT Appoints New Chief Executive Officer 3
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
Medicine Products: